Similar articles

• Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis.

  Culberson JC, Bush BL, Sardana VV. Culberson JC, et al. Methods Enzymol. 1994;241:385-94. doi: 10.1016/0076-6879(94)41075-5. Methods Enzymol. 1994. PMID: 7854190 Review. No abstract available.
• Time dependent heterodimer formation leads to inhibition of HIV protease activity.

  Babé LM, Craik CS. Babé LM, et al. Adv Exp Med Biol. 1991;306:543-7. doi: 10.1007/978-1-4684-6012-4_74. Adv Exp Med Biol. 1991. PMID: 1812756 No abstract available.
• Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.

  Tong L, Pav S, Pargellis C, Dô F, Lamarre D, Anderson PC. Tong L, et al. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8387-91. doi: 10.1073/pnas.90.18.8387. Proc Natl Acad Sci U S A. 1993. PMID: 8378311 Free PMC article.
• Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.

  Savarino A, Cauda R, Cassone A. Savarino A, et al. J Infect Dis. 2005 Apr 15;191(8):1381-2; author reply 1382-3. doi: 10.1086/428781. J Infect Dis. 2005. PMID: 15776390 No abstract available.
• Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates.

  Tomasselli AG, Heinrikson RL. Tomasselli AG, et al. Methods Enzymol. 1994;241:279-301. doi: 10.1016/0076-6879(94)41069-0. Methods Enzymol. 1994. PMID: 7854182 Review. No abstract available.